Kymera Therapeutics (KYMR)
(Real Time Quote from BATS)
$35.35 USD
-0.66 (-1.83%)
Updated May 21, 2024 02:30 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Income Statements
Fiscal Year end for Kymera Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 79 | 47 | 73 | 34 | 3 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 79 | 47 | 73 | 34 | 3 |
Selling & Adminstrative & Depr. & Amort Expenses | 244 | 208 | 173 | 80 | 45 |
Income After Depreciation & Amortization | -166 | -161 | -101 | -46 | -42 |
Non-Operating Income | 19 | 7 | 0 | 1 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -147 | -155 | -100 | -46 | -41 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -147 | -155 | -100 | -46 | -41 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -147 | -155 | -100 | -46 | -41 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -167 | -157 | -92 | -43 | -41 |
Depreciation & Amortization (Cash Flow) | -2 | 4 | 8 | 3 | 1 |
Income After Depreciation & Amortization | -166 | -161 | -101 | -46 | -42 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 58.37 | 53.93 | 47.99 | 17.35 | NA |
Diluted EPS Before Non-Recurring Items | -2.52 | -2.87 | -2.09 | -3.15 | NA |
Diluted Net EPS (GAAP) | -2.52 | -2.87 | -2.09 | -3.15 | NA |
Fiscal Year end for Kymera Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 10.29 | 47.89 | 4.73 | 16.51 | 9.47 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 10.29 | 47.89 | 4.73 | 16.51 | 9.47 |
SG&A, R&D, and Dept/Amort Expenses | 68.12 | 67.20 | 62.24 | 59.90 | 54.80 |
Income After SG&A, R&D, and Dept/Amort Expenses | -57.83 | -19.31 | -57.51 | -43.39 | -45.33 |
Non-Operating Income | 9.34 | 5.00 | 4.68 | 4.63 | 4.45 |
Interest Expense | 0.07 | 0.05 | 0.04 | 0.05 | 0.06 |
Pretax Income | -48.56 | -14.37 | -52.87 | -38.80 | -40.93 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -48.56 | -14.37 | -52.87 | -38.80 | -40.93 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -48.56 | -14.37 | -52.87 | -38.80 | -40.93 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 70.77 | 58.52 | 58.42 | 58.33 | 58.19 |
Diluted EPS Before Non-Recurring Items | -0.69 | -0.25 | -0.90 | -0.67 | -0.70 |
Diluted Net EPS (GAAP) | -0.69 | -0.25 | -0.90 | -0.67 | -0.70 |